Launch of the GSD NovaPrime® SARS-CoV-2 Direct RT-PCR
The GSD NovaPrime® SARS-CoV-2 Direct RT-PCR is intended for the qualitative detection of SARS-CoV-2 from human nasopharyngeal swabs, eluted directly into deionised water without an additional RNA extraction process (extraction-free).
Increase of global SARS-CoV-2 testing worldwide has posed new challenges to laboratories in nearly all countries. More than ever, there is a critical need for rapid molecular solutions to increase testing capacity, and provide accurate and faster results. Removing the RNA extraction step helps to meet this challenge, by increasing the number of laboratories that can perform these tests, allowing more tests to be performed and reducing the cost, labour, and time required to carry out very sensitive PCR tests.
The GSD NovaPrime® SARS-CoV-2 Direct RT-PCR is CE marked and has been validated as an extraction-free method. This new workflow shortens the complete turnaround time of the test, providing results in approximately one hour from sample to result without compromising the high accuracy of PCR testing, and allowing for a higher processing capacity.
Saliva and pharynx gargle samples validation for the GSD NovaPrime® SARS-CoV-2 (COVID-19)
The GSD NovaPrime® SARS-CoV-2 (COVID-19) has now been successfully validated for pharynx gargle and saliva samples. These new matrices constitute an easy-to-use sampling method that is particularly useful for self-sampling applications and are suitable for children.
This test is a highly sensitive multiplex real-time PCR assay intended for the qualitative determination of SARS-CoV-2 genomic RNA in respiratory samples. The assay simultaneously detects two target sequences in the N gene.
For more information, visit this page. These tests are not for sale outside of Europe at the moment.
For further information:
About Eurofins Technologies
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast-growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
For further information, visit the Eurofins Technologies website.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
Eurofins BioPharma Services, Laboratory Testing is a full service global organization with dedicated testing facilities for Early Clinical Development, Central Laboratory Services, Bioanalytical Services, Virology and Immunology Testing Services, Anatomic Pathology and Genomics Services. As a division of the Eurofins Scientific Group, our sole and only focus is clinical laboratory analysis.